These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16480436)

  • 21. Assessing emerging infectious threats to blood safety for the blood disorders community.
    Trimble SR; Parker CS; Grant AM; Soucie JM; Reyes N
    Am J Prev Med; 2010 Apr; 38(4 Suppl):S468-74. PubMed ID: 20331945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates.
    Berger K; Bauer M; Schopohl D; Henschler R; Ostermann H
    Onkologie; 2013; 36(1-2):53-9. PubMed ID: 23429333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transfusion-transmitted infections: existing and emerging pathogens.
    Kaur P; Basu S
    J Postgrad Med; 2005; 51(2):146-51. PubMed ID: 16006714
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reengineering transfusion and cellular therapy processes hospitalwide: ensuring the safe utilization of blood products.
    Brooks JP
    Transfusion; 2005 Oct; 45(4 Suppl):159S-71S. PubMed ID: 16181401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The virucidal effect of platelet concentrates: preliminary study and first conclusions.
    Maurice A; Marchand-Arvier M; Edert D; Le Faou A; Gondrexon G; Vigneron C
    Platelets; 2002 Jun; 13(4):219-22. PubMed ID: 12189023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogen reduction: state of reflection in Ireland.
    Murphy WG
    Transfus Clin Biol; 2011 Aug; 18(4):488-90. PubMed ID: 21803629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pathogen inactivation of platelets: organization consequences for platelet transfusion].
    Chavarin P; DePutter C; Boussoulade F; Acquart S; Vidal M; Argaud C; Fabrigli P; Garraud O
    Transfus Clin Biol; 2011 Aug; 18(4):472-7. PubMed ID: 21783400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of pathogen reduction technology for plasma and platelets in Québec: A focus on potential emerging pathogens.
    Grégoire Y; Delage G; Custer B; Rochette S; Renaud C; Lewin A; Germain M
    Transfusion; 2022 Jun; 62(6):1208-1217. PubMed ID: 35560238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmaco-economics of blood transfusion safety: review of the available evidence.
    van Hulst M; de Wolf JT; Staginnus U; Ruitenberg EJ; Postma MJ
    Vox Sang; 2002 Aug; 83(2):146-55. PubMed ID: 12201844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system.
    Cicchetti A; Coretti S; Sacco F; Rebulla P; Fiore A; Rumi F; Di Bidino R; Urbina LI; Refolo P; Sacchini D; Spagnolo AG; Midolo E; Marano G; Farina B; Pati I; Veropalumbo E; Pupella S; Liumbruno GM
    Blood Transfus; 2018 Nov; 16(6):483-489. PubMed ID: 30201081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets.
    Lopez-Plaza I; Weissfeld J; Triulzi DJ
    Transfusion; 1999 Sep; 39(9):925-32. PubMed ID: 10533816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The physician's role in selecting a factor replacement therapy.
    Pipe SW
    Haemophilia; 2006 Mar; 12 Suppl 1():21-5; discussion 26-8. PubMed ID: 16445814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A new era of transfusion-transmitted pathogens, infections. Renewed need for updating standards for clinicans along with blood banking].
    Udvardy M
    Orv Hetil; 2018 Sep; 159(37):1495-1500. PubMed ID: 30196714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Issues in transfusion safety.
    Rushton AR; Jennings PR
    JAAPA; 2004 May; 17(5):39-42, 44, 46. PubMed ID: 15305503
    [No Abstract]   [Full Text] [Related]  

  • 35. [Prophylactic platelet transfusion in patients with hematologic diseases].
    Siitonen T; Koistinen P
    Duodecim; 2004; 120(7):877-84. PubMed ID: 15154309
    [No Abstract]   [Full Text] [Related]  

  • 36. [Platelet transfusion; concentrates from single or from multiple donors?].
    Lozano ML; Vicente V
    Med Clin (Barc); 2004 Feb; 122(4):145-9. PubMed ID: 14967098
    [No Abstract]   [Full Text] [Related]  

  • 37. Early recognition and reporting of suspected bacterial contamination may prevent transfusion transmission of infection by associated units.
    Cawley C; McDonald C; Ancliff S; Roy A; MacLennan S; Brant L; Pichon B; Brailsford S
    Transfus Med; 2011 Feb; 21(1):70-2. PubMed ID: 21039982
    [No Abstract]   [Full Text] [Related]  

  • 38. Blood transfusions in children with cancer and hematologic disorders: why, when, and how?
    Buchanan GR
    Pediatr Blood Cancer; 2005 Feb; 44(2):114-6. PubMed ID: 15578665
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and usefulness of autologous cryopreserved platelets.
    Perseghin P; Dassi M
    Lancet; 2002 Dec; 360(9349):1985-6; author reply 1986. PubMed ID: 12493311
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical effectiveness and comparative hospital costs of different platelet dose strategies.
    Assi TB; Haddad A; Baz E
    Blood Transfus; 2014 Jul; 12(3):307-13. PubMed ID: 25074523
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.